- Home
- IMTX vs ANAB Comparison
IMTX vs ANAB Comparison
Compare IMTX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | ANAB |
|---|---|---|
| Founded | N/A | 2005 |
| Country | Germany | United States |
| Employees | 407 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | IMTX | ANAB |
|---|---|---|
| Price | $10.91 | $70.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $19.00 | ★ $74.64 |
| AVG Volume (30 Days) | 361.6K | ★ 553.9K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.91 | $31.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $3.94 | $17.11 |
| 52 Week High | $12.41 | $73.30 |
Technical Indicators
Market Signals| Indicator | IMTX | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 65.81 |
| Support Level | $9.66 | $53.46 |
| Resistance Level | $11.30 | N/A |
| Average True Range (ATR) | 0.49 | 4.40 |
| MACD | 0.13 | 0.83 |
| Stochastic Oscillator | 88.71 | 84.92 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).